The phososphodiesterase-5 inhibitor, sildenafil, or more commonly referred to as Viagra, has proven to have promising effects on treating pulmonary hypertension, a leading cause of mortality in infants. In infants, pulmonary hypertension occurs when the pulmonary blood pressure remains so high, that the blood often bypasses the lungs and goes directly into the systematic circuit without picking up the vital oxygen from the lungs that the body needs. The drug is currently being marketed by Pfizer as an anti-impotence drug which is known to enhance the effect of nitric oxide (NO) by inhibiting the enzyme, phosphodiesterase type 5 which is responsible for the degradation of cyclic GMP. It has been discovered that the lung tissue is also abundant in the phosphodiesterase type 5 enzymes. By inhibiting this enzyme, it has shown to have vasodilating properties within the pulmonary circuit in both adults and infants.
|Presenter:||Denise D'Angelo (Undergraduate Student)|
|Time:||2 pm (Session III)|